Jaffetilchin Investment Partners, LLC Rigel Pharmaceuticals Inc Transaction History

Jaffetilchin Investment Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 25, 2021	SELL	$3.5 - $4.5 $325,258 - $418,189	-92,931 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$3.09 - $4.54 $287,156 - $421,906	92,931 New	92,931 $325,000
Q1 2021 May 10, 2021	SELL	$3.35 - $4.93 $311,318 - $458,149	-92,931 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.35 - $3.74 $89,081 - $141,772	37,907 Added 68.89%	92,931 $325,000
Q3 2020 Nov 09, 2020	BUY	$1.78 - $4.13 $55,156 - $127,976	30,987 Added 128.91%	55,024 $132,000
Q2 2020 Aug 03, 2020	BUY	$1.41 - $2.05 $33,892 - $49,275	24,037 New	24,037 $44,000
Q3 2019 Oct 15, 2019	SELL	$1.63 - $2.62 $67,341 - $108,242	-41,314 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$2.02 - $2.61 $83,454 - $107,829	41,314 New	41,314 $108,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Jaffetilchin Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Jaffetilchin Investment Partners, LLC with notifications on news.